Glycolytic regulatory enzyme PFKFB3 as a prognostic and tumor microenvironment biomarker in human cancers

Qingen Da, Lei Huang, Can Huang, Ze’e Chen, Zhitong Jiang, Fang Huang, Tao Shen, Lu Sun, Zilong Yan, Xiaoqiang Ye, Jing Yi, Yu Huang, Jingjing Da, Mingming Ren, Jikui Liu, Tao Wang, Zhen Han, Kunfu OuyangAging 2023 · DOI

Abstract

The 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFK-2/FBPase-2, PFKFB3) is a glycolysis regulatory enzyme and plays a key role in oncogenesis of several cancers. However, the systematic study of crosstalk between PFKFB3 and Tumor microenvironment (TME) in pan-cancer has less been examined. In this study, we conducted a comprehensive analysis of the relationship between PFKFB3 expression, patient prognostic, Tumor mutational burden (TMB), Microsatellite instability (MSI), DNA mismatch repair (MMR), and especially TME, including immune infiltration, immune regulator, and immune checkpoint, across 33 types of tumors using datasets of The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). We found that PFKFB3 expression was significantly correlated with patient prognostic and TME factors in various tumors. Moreover, we confirmed that PFKFB3 was an independent prognostic factor for kidney renal papillary cell carcinoma (KIRP), and established a risk prognostic model based on the expression of PFKFB3 as a clinical risk factor, which has a good predictive ability. Our study indicated that PFKFB3 is a potent regulatory factor for TME and has the potential to be a valuable prognostic biomarker in human tumor therapy.

Introduction

Most cancer cells undergo metabolic reprogramming, famously known as the Warburg Effect, where they prioritize glycolysis over oxidative phosphorylation to fuel rapid growth. The enzyme PFKFB3 is a master regulator of this process. While its role in metabolism is well-documented, its broader impact on the Tumor Microenvironment (TME)—the ecosystem of immune cells and signaling molecules surrounding a tumor—has remained less clear. This study performs a comprehensive pan-cancer analysis to bridge this gap, examining how PFKFB3 expression correlates with immune infiltration, genetic instability, and patient prognosis.

Methods

This study utilized a multi-omic bioinformatic approach, integrating data from several foundational biological databases:

  • Transcriptomics & Proteomics: mRNA and protein levels were compared between tumor and normal tissues using TCGA, GTEx, and CPTAC datasets.
  • Post-translational Modifications: Phosphorylation levels were analyzed to understand how the enzyme is regulated at the protein level.
  • Immune Profiling: Algorithms like CIBERSORT and TIMER2.0 estimated the abundance of immune cells (e.g., T-cells, macrophages) within tumors.
  • Genetic Metrics: Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI) were calculated as indicators of immunotherapy response.
  • Prognostic Modeling: A Cox regression-based risk model was developed specifically for kidney renal papillary cell carcinoma (KIRP).

Key Results

Context-Dependent Expression and Multi-level Regulation

PFKFB3 expression is highly tissue-specific. While significantly elevated in cancers like colon and stomach adenocarcinoma, it is lower in others, such as breast cancer, compared to normal tissues.

Figure 1: Pan-cancer mRNA expression levels of PFKFB3 across TCGA datasets compared to normal tissues.

Beyond mRNA, the study analyzed protein levels and phosphorylation. Significant alterations in protein expression were observed in several cancers, and specific phosphorylation sites (S22, S461, and S441) were found to be differentially regulated in tumors, suggesting their role as molecular "switches" for enzyme activity.

Figure 6: Comprehensive overview of PFKFB3 analysis, including mRNA expression (A), clinical stage correlation (B), protein levels (C), and phosphorylation levels (D).

Immune Crosstalk and the Metabolic Shield

A striking finding is the strong correlation between PFKFB3 and the infiltration of immunosuppressive cells, such as macrophages and neutrophils. Conversely, PFKFB3 often negatively correlates with natural killer (NK) cells. Furthermore, PFKFB3 expression was remarkably synchronized with the expression of immune checkpoints (like PD-L1 and CTLA4) in 17 different tumor types. This suggests that high PFKFB3 might help tumors create a metabolic "shield" that prevents the immune system from attacking.

Prognostic Power and the KIRP Risk Model

High PFKFB3 expression was a significant predictor of poor Overall Survival (OS) in several cancers, including Adrenocortical Carcinoma (ACC) and Liver Hepatocellular Carcinoma (LIHC). Notably, PFKFB3 was confirmed as an independent prognostic factor for kidney renal papillary cell carcinoma (KIRP). The researchers built a clinical risk model for KIRP patients that demonstrated good predictive ability for 1-year and 3-year survival rates.

Discussion and Conclusion

This pan-cancer analysis identifies PFKFB3 as a dual-threat biomarker that drives both metabolic reprogramming and immune evasion. The synchronization of PFKFB3 with immune checkpoints suggests that targeting this enzyme could potentially "re-sensitize" tumors to immunotherapy by disrupting the metabolic-immune crosstalk. While these bioinformatic correlations are robust, future "wet lab" experiments are necessary to confirm the exact molecular mechanisms. Nevertheless, PFKFB3 emerges as a promising target for integrated metabolic and immune-based cancer therapies.

Summary updated

Abstract

The 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFK-2/FBPase-2, PFKFB3) is a glycolysis regulatory enzyme and plays a key role in oncogenesis of several cancers. However, the systematic study of crosstalk between PFKFB3 and Tumor microenvironment (TME) in pan-cancer has less been examined. In this study, we conducted a comprehensive analysis of the relationship between <i>PFKFB3</i> expression, patient prognostic, Tumor mutational burden (TMB), Microsatellite instability (MSI), DNA mismatch repair (MMR), and especially TME, including immune infiltration, immune regulator, and immune checkpoint, across 33 types of tumors using datasets of The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). We found that <i>PFKFB3</i> expression was significantly correlated with patient prognostic and TME factors in various tumors. Moreover, we confirmed that PFKFB3 was an independent prognostic factor for kidney renal papillary cell carcinoma (KIRP), and established a risk prognostic model based on the expression of <i>PFKFB3</i> as a clinical risk factor, which has a good predictive ability. Our study indicated that PFKFB3 is a potent regulatory factor for TME and has the potential to be a valuable prognostic biomarker in human tumor therapy.
BibTeX
@inproceedings{da2023glycolytic,
  author = {Qingen Da and Lei Huang and Can Huang and Ze’e Chen and Zhitong Jiang and Fang Huang and Tao Shen and Lu Sun and Zilong Yan and Xiaoqiang Ye and Jing Yi and Yu Huang and Jingjing Da and Mingming Ren and Jikui Liu and Tao Wang and Zhen Han and Kunfu Ouyang},
  title = {{Glycolytic regulatory enzyme PFKFB3 as a prognostic and tumor microenvironment biomarker in human cancers}},
  booktitle = {Aging},
  year = {2023},
  doi = {10.18632/aging.204758},
}
Figure